Preventing and reversing corneal scarring using a specific inhibitor
VRC Inhibiting p38 to Prevent and Restore Corneal Scarring
This study is looking at a new treatment that could help prevent and heal corneal scarring from injuries, which might improve vision and lower the chance of blindness for people with these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schepens Eye Research Institute NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10910222 on NIH RePORTER |
What this research studies
This research investigates the use of a p38 MAPK inhibitor, SB202190, to prevent and reverse corneal scarring caused by injuries. The study aims to understand how this inhibitor can block the transformation of normal corneal cells into scar-forming cells, potentially leading to new, non-invasive treatments for corneal fibrosis. By utilizing both in vivo and in vitro models, the research seeks to demonstrate the effectiveness of this approach in reducing scarring and restoring normal corneal function. Patients may benefit from a new therapeutic option that could improve vision and reduce the risk of blindness due to corneal injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced corneal injuries or lacerations leading to scarring.
Not a fit: Patients with corneal scarring due to non-injury related causes or those who have already undergone invasive treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel, non-invasive treatment option for patients suffering from corneal scarring, potentially restoring vision and preventing blindness.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting the p38 MAPK pathway in other fibrotic conditions, suggesting potential for success in this area.
Where this research is happening
Boston, United States
- Schepens Eye Research Institute — Boston, United States (Active)
Researchers
- Principal investigator: Ciolino, Joseph B. — Schepens Eye Research Institute
- Study coordinator: Ciolino, Joseph B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.